-
1
-
-
67650874081
-
Cancer statistics, 2009
-
Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
-
(2009)
CA Cancer J Clin
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
3
-
-
0022352068
-
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome
-
Stam K., Heisterkamp N., Grosveld G., de Klein A., Verma R.S., Coleman M., et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 1985, 313:1429-1433.
-
(1985)
N Engl J Med
, vol.313
, pp. 1429-1433
-
-
Stam, K.1
Heisterkamp, N.2
Grosveld, G.3
de Klein, A.4
Verma, R.S.5
Coleman, M.6
-
4
-
-
0021346853
-
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
-
Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
-
(1984)
Cell
, vol.36
, pp. 93-99
-
-
Groffen, J.1
Stephenson, J.R.2
Heisterkamp, N.3
de Klein, A.4
Bartram, C.R.5
Grosveld, G.6
-
5
-
-
0000286732
-
A minute chromosome in human chronic granulocytic leukemia (abstract)
-
Nowell P.C., Hungerford D. A minute chromosome in human chronic granulocytic leukemia (abstract). Science 1960, 132:1497.
-
(1960)
Science
, vol.132
, pp. 1497
-
-
Nowell, P.C.1
Hungerford, D.2
-
6
-
-
0015694748
-
Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
-
Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
-
(1973)
Nature
, vol.243
, pp. 290-293
-
-
Rowley, J.D.1
-
7
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
-
(1996)
Nat Med
, vol.2
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
Ohno, S.4
Segal, G.M.5
Fanning, S.6
-
8
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
-
Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
-
(2001)
N Engl J Med
, vol.344
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.J.3
Peng, B.4
Buchdunger, E.5
Ford, J.M.6
-
9
-
-
0037085785
-
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
-
Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928-1937.
-
(2002)
Blood
, vol.99
, pp. 1928-1937
-
-
Talpaz, M.1
Silver, R.T.2
Druker, B.J.3
Goldman, J.M.4
Gambacorti-Passerini, C.5
Guilhot, F.6
-
10
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
-
11
-
-
0037186915
-
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
-
Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
-
(2002)
N Engl J Med
, vol.346
, pp. 645-652
-
-
Kantarjian, H.1
Sawyers, C.2
Hochhaus, A.3
Guilhot, F.4
Schiffer, C.5
Gambacorti-Passerini, C.6
-
12
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
-
(2006)
N Engl J Med
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
-
13
-
-
77949767505
-
International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
-
Deininger M., O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts 2009, 114:1126-
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Deininger, M.1
O'Brien, S.G.2
Guilhot, F.3
Goldman, J.M.4
Hochhaus, A.5
Hughes, T.P.6
-
14
-
-
49149111543
-
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
-
de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3358-3363
-
-
de Lavallade, H.1
Apperley, J.F.2
Khorashad, J.S.3
Milojkovic, D.4
Reid, A.G.5
Bua, M.6
-
15
-
-
54049130762
-
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
-
Lucas C.M., Wang L., Austin G.M., Knight K., Watmough S.J., Shwe K.H., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008, 22:1963-1966.
-
(2008)
Leukemia
, vol.22
, pp. 1963-1966
-
-
Lucas, C.M.1
Wang, L.2
Austin, G.M.3
Knight, K.4
Watmough, S.J.5
Shwe, K.H.6
-
16
-
-
25444488489
-
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
-
Barnes D.J., Palaiologou D., Panousopoulou E., Schultheis B., Yong A.S.M., Wong A., et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005, 65:8912-8919.
-
(2005)
Cancer Res
, vol.65
, pp. 8912-8919
-
-
Barnes, D.J.1
Palaiologou, D.2
Panousopoulou, E.3
Schultheis, B.4
Yong, A.S.M.5
Wong, A.6
-
17
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
-
(2001)
Science
, vol.293
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
Hsu, N.4
Paquette, R.5
Rao, P.N.6
-
18
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
-
(2002)
Cancer Cell
, vol.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
Gorre, M.E.4
Paquette, R.L.5
Kuriyan, J.6
-
19
-
-
33847191776
-
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
-
Sherbenou D.W., Wong M.J., Humayun A., McGreevey L.S., Harrell P., Yang R., et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007, 21:489-493.
-
(2007)
Leukemia
, vol.21
, pp. 489-493
-
-
Sherbenou, D.W.1
Wong, M.J.2
Humayun, A.3
McGreevey, L.S.4
Harrell, P.5
Yang, R.6
-
20
-
-
33745102555
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
-
Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
-
(2006)
N Engl J Med
, vol.354
, pp. 2531-2541
-
-
Talpaz, M.1
Shah, N.P.2
Kantarjian, H.3
Donato, N.4
Nicoll, J.5
Paquette, R.6
-
21
-
-
9444282642
-
Active transport of imatinib into and out of cells: implications for drug resistance
-
Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745.
-
(2004)
Blood
, vol.104
, pp. 3739-3745
-
-
Thomas, J.1
Wang, L.2
Clark, R.E.3
Pirmohamed, M.4
-
22
-
-
3943088431
-
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
-
Jamieson C.H.M., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667.
-
(2004)
N Engl J Med
, vol.351
, pp. 657-667
-
-
Jamieson, C.H.M.1
Ailles, L.E.2
Dylla, S.J.3
Muijtjens, M.4
Jones, C.5
Zehnder, J.L.6
-
23
-
-
34548825795
-
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
-
O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
-
(2007)
Blood
, vol.110
, pp. 2242-2249
-
-
O'Hare, T.1
Eide, C.A.2
Deininger, M.W.3
-
24
-
-
33846228789
-
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
-
Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12:7374-7379.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7374-7379
-
-
Soverini, S.1
Colarossi, S.2
Gnani, A.3
Rosti, G.4
Castagnetti, F.5
Poerio, A.6
-
25
-
-
23044458596
-
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
-
Soverini S., Martinelli G., Rosti G., Bassi S., Amabile M., Poerio A., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005, 23:4100-4109.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4100-4109
-
-
Soverini, S.1
Martinelli, G.2
Rosti, G.3
Bassi, S.4
Amabile, M.5
Poerio, A.6
-
26
-
-
10744232328
-
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
-
Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
-
(2003)
Blood
, vol.102
, pp. 276-283
-
-
Branford, S.1
Rudzki, Z.2
Walsh, S.3
Parkinson, I.4
Grigg, A.5
Szer, J.6
-
27
-
-
73949105873
-
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
-
Muller M.C., Cortes J.E., Kim D.-W., Druker B.J., Erben P., Pasquini R., et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009, 114:4944-4953.
-
(2009)
Blood
, vol.114
, pp. 4944-4953
-
-
Muller, M.C.1
Cortes, J.E.2
Kim, D.-W.3
Druker, B.J.4
Erben, P.5
Pasquini, R.6
-
28
-
-
54349089682
-
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
-
Khorashad J.S., de Lavallade H., Apperley J.F., Milojkovic D., Reid A.G., Bua M., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008, 26:4806-4813.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4806-4813
-
-
Khorashad, J.S.1
de Lavallade, H.2
Apperley, J.F.3
Milojkovic, D.4
Reid, A.G.5
Bua, M.6
-
29
-
-
34848911943
-
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
-
Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562-2569.
-
(2007)
J Clin Invest
, vol.117
, pp. 2562-2569
-
-
Shah, N.P.1
Skaggs, B.J.2
Branford, S.3
Hughes, T.P.4
Nicoll, J.M.5
Paquette, R.L.6
-
30
-
-
76249090055
-
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
-
Branford S., Melo J.V., Hughes T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 2009, 114:5426-5435.
-
(2009)
Blood
, vol.114
, pp. 5426-5435
-
-
Branford, S.1
Melo, J.V.2
Hughes, T.P.3
-
31
-
-
9444264703
-
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
-
Nowicki M.O., Falinski R., Koptyra M., Slupianek A., Stoklosa T., Gloc E., et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004, 104:3746-3753.
-
(2004)
Blood
, vol.104
, pp. 3746-3753
-
-
Nowicki, M.O.1
Falinski, R.2
Koptyra, M.3
Slupianek, A.4
Stoklosa, T.5
Gloc, E.6
-
32
-
-
42349116637
-
BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations
-
Stoklosa T., Poplawski T., Koptyra M., Nieborowska-Skorska M., Basak G., Slupianek A., et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008, 68:2576-2580.
-
(2008)
Cancer Res
, vol.68
, pp. 2576-2580
-
-
Stoklosa, T.1
Poplawski, T.2
Koptyra, M.3
Nieborowska-Skorska, M.4
Basak, G.5
Slupianek, A.6
-
33
-
-
0141816691
-
P210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation
-
Canitrot Y., Falinski R., Louat T., Laurent G., Cazaux C., Hoffmann J.S., et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003, 102:2632-2637.
-
(2003)
Blood
, vol.102
, pp. 2632-2637
-
-
Canitrot, Y.1
Falinski, R.2
Louat, T.3
Laurent, G.4
Cazaux, C.5
Hoffmann, J.S.6
-
34
-
-
70349251859
-
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair
-
Fernandes M.S., Reddy M.M., Gonneville J.R., DeRoo S.C., Podar K., Griffin J.D., et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009, 114:1813-1819.
-
(2009)
Blood
, vol.114
, pp. 1813-1819
-
-
Fernandes, M.S.1
Reddy, M.M.2
Gonneville, J.R.3
DeRoo, S.C.4
Podar, K.5
Griffin, J.D.6
-
35
-
-
43249083718
-
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
-
Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
-
(2008)
Blood
, vol.111
, pp. 4022-4028
-
-
Larson, R.A.1
Druker, B.J.2
Guilhot, F.3
O'Brien, S.G.4
Riviere, G.J.5
Krahnke, T.6
-
36
-
-
67049087117
-
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
-
Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
-
(2009)
Blood
, vol.113
, pp. 5401-5411
-
-
Noens, L.1
van Lierde, M.A.2
De Bock, R.3
Verhoef, G.4
Zachee, P.5
Berneman, Z.6
-
37
-
-
77952467377
-
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
-
Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2381-2388
-
-
Marin, D.1
Bazeos, A.2
Mahon, F.X.3
Eliasson, L.4
Milojkovic, D.5
Bua, M.6
-
38
-
-
77953934202
-
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
-
Green H., Skoglund K., Rommel F., Mirghani R.A., Lotfi K. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol 2010, 66:383-386.
-
(2010)
Eur J Clin Pharmacol
, vol.66
, pp. 383-386
-
-
Green, H.1
Skoglund, K.2
Rommel, F.3
Mirghani, R.A.4
Lotfi, K.5
-
40
-
-
0042305479
-
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients
-
Gambacorti-Passerini C., Zucchetti M., Russo D., Frapolli R., Verga M., Bungaro S., et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9:625-632.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 625-632
-
-
Gambacorti-Passerini, C.1
Zucchetti, M.2
Russo, D.3
Frapolli, R.4
Verga, M.5
Bungaro, S.6
-
41
-
-
10744232038
-
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo
-
Larghero J., Leguay T., Mourah S., Madelaine-Chambrin I., Taksin A.L., Raffoux E., et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 2003, 66:1907-1913.
-
(2003)
Biochem Pharmacol
, vol.66
, pp. 1907-1913
-
-
Larghero, J.1
Leguay, T.2
Mourah, S.3
Madelaine-Chambrin, I.4
Taksin, A.L.5
Raffoux, E.6
-
42
-
-
33750735723
-
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
-
Delbaldo C., Chatelut E., Re M., Deroussent A., Seronie-Vivien S., Jambu A., et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006, 12:6073-6078.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6073-6078
-
-
Delbaldo, C.1
Chatelut, E.2
Re, M.3
Deroussent, A.4
Seronie-Vivien, S.5
Jambu, A.6
-
43
-
-
0034684075
-
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
-
Gambacorti-Passerini C., Barni R., le Coutre P., Zucchetti M., Cabrita G., Cleris L., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000, 92:1641-1650.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 1641-1650
-
-
Gambacorti-Passerini, C.1
Barni, R.2
le Coutre, P.3
Zucchetti, M.4
Cabrita, G.5
Cleris, L.6
-
44
-
-
38349193809
-
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
-
Wang L., Giannoudis A., Lane S., Williamson P., Pirmohamed M., Clark R.E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008, 83:258-264.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 258-264
-
-
Wang, L.1
Giannoudis, A.2
Lane, S.3
Williamson, P.4
Pirmohamed, M.5
Clark, R.E.6
-
45
-
-
37049028176
-
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
-
White D.L., Saunders V.A., Dang P., Engler J., Venables A., Zrim S., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110:4064-4072.
-
(2007)
Blood
, vol.110
, pp. 4064-4072
-
-
White, D.L.1
Saunders, V.A.2
Dang, P.3
Engler, J.4
Venables, A.5
Zrim, S.6
-
46
-
-
77954936879
-
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
-
White D.L., Dang P., Engler J., Frede A., Zrim S., Osborn M., et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010, 28:2761-2767.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2761-2767
-
-
White, D.L.1
Dang, P.2
Engler, J.3
Frede, A.4
Zrim, S.5
Osborn, M.6
-
47
-
-
77950959714
-
Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity
-
Engler J.R., Frede A., Saunders V.A., Zannettino A.C., Hughes T.P., White D.L. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010, 24:765-770.
-
(2010)
Leukemia
, vol.24
, pp. 765-770
-
-
Engler, J.R.1
Frede, A.2
Saunders, V.A.3
Zannettino, A.C.4
Hughes, T.P.5
White, D.L.6
-
48
-
-
77957937825
-
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
-
[blood-2010-01-267013]
-
Engler J.R., Frede A., Saunders V., Zannettino A., White D.L., Hughes T.P. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood 2010, [blood-2010-01-267013].
-
(2010)
Blood
-
-
Engler, J.R.1
Frede, A.2
Saunders, V.3
Zannettino, A.4
White, D.L.5
Hughes, T.P.6
-
49
-
-
0033197989
-
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance
-
Giles F.J., Kantarjian H.M., Cortes J., Thomas D.A., Talpaz M., Manshouri T., et al. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer 1999, 86:805-813.
-
(1999)
Cancer
, vol.86
, pp. 805-813
-
-
Giles, F.J.1
Kantarjian, H.M.2
Cortes, J.3
Thomas, D.A.4
Talpaz, M.5
Manshouri, T.6
-
50
-
-
0037443754
-
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
-
Mahon F.X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101:2368-2373.
-
(2003)
Blood
, vol.101
, pp. 2368-2373
-
-
Mahon, F.X.1
Belloc, F.2
Lagarde, V.3
Chollet, C.4
Moreau-Gaudry, F.5
Reiffers, J.6
-
51
-
-
34250708413
-
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels
-
[author reply 2-4]
-
Widmer N., Rumpold H., Untergasser G., Fayet A., Buclin T., Decosterd L.A. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 2007, 21:1561-1562. [author reply 2-4].
-
(2007)
Leukemia
, vol.21
, pp. 1561-1562
-
-
Widmer, N.1
Rumpold, H.2
Untergasser, G.3
Fayet, A.4
Buclin, T.5
Decosterd, L.A.6
-
52
-
-
20444482337
-
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines
-
Rumpold H., Wolf A.M., Gruenewald K., Gastl G., Gunsilius E., Wolf D. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005, 33:767-775.
-
(2005)
Exp Hematol
, vol.33
, pp. 767-775
-
-
Rumpold, H.1
Wolf, A.M.2
Gruenewald, K.3
Gastl, G.4
Gunsilius, E.5
Wolf, D.6
-
53
-
-
67349280901
-
Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib
-
Hatziieremia S., Jordanides N.E., Holyoake T.L., Mountford J.C., Jorgensen H.G. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009, 37:692-700.
-
(2009)
Exp Hematol
, vol.37
, pp. 692-700
-
-
Hatziieremia, S.1
Jordanides, N.E.2
Holyoake, T.L.3
Mountford, J.C.4
Jorgensen, H.G.5
-
54
-
-
52649177063
-
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
-
Dulucq S., Bouchet S., Turcq B., Lippert E., Etienne G., Reiffers J., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
-
(2008)
Blood
, vol.112
, pp. 2024-2027
-
-
Dulucq, S.1
Bouchet, S.2
Turcq, B.3
Lippert, E.4
Etienne, G.5
Reiffers, J.6
-
55
-
-
0030061157
-
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
-
Majlis A., Smith T., Talpaz M., O'Brien S., Rios M., Kantarjian H. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996, 14:196-203.
-
(1996)
J Clin Oncol
, vol.14
, pp. 196-203
-
-
Majlis, A.1
Smith, T.2
Talpaz, M.3
O'Brien, S.4
Rios, M.5
Kantarjian, H.6
-
56
-
-
34250180917
-
Characterization of Ph-negative abnormal clones emerging during imatinib therapy
-
Abruzzese E., Gozzetti A., Galimberti S., Trawinska M.M., Caravita T., Siniscalchi A., et al. Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer 2007, 109:2466-2472.
-
(2007)
Cancer
, vol.109
, pp. 2466-2472
-
-
Abruzzese, E.1
Gozzetti, A.2
Galimberti, S.3
Trawinska, M.M.4
Caravita, T.5
Siniscalchi, A.6
-
57
-
-
69249236962
-
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia
-
Klemm L., Duy C., Iacobucci I., Kuchen S., von Levetzow G., Feldhahn N., et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009, 16:232-245.
-
(2009)
Cancer Cell
, vol.16
, pp. 232-245
-
-
Klemm, L.1
Duy, C.2
Iacobucci, I.3
Kuchen, S.4
von Levetzow, G.5
Feldhahn, N.6
-
58
-
-
33644643189
-
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations
-
Ramiro A.R., Jankovic M., Callen E., Difilippantonio S., Chen H.T., McBride K.M., et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006, 440:105-109.
-
(2006)
Nature
, vol.440
, pp. 105-109
-
-
Ramiro, A.R.1
Jankovic, M.2
Callen, E.3
Difilippantonio, S.4
Chen, H.T.5
McBride, K.M.6
-
59
-
-
37549068541
-
AID is required for germinal center-derived lymphomagenesis
-
Pasqualucci L., Bhagat G., Jankovic M., Compagno M., Smith P., Muramatsu M., et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008, 40:108-112.
-
(2008)
Nat Genet
, vol.40
, pp. 108-112
-
-
Pasqualucci, L.1
Bhagat, G.2
Jankovic, M.3
Compagno, M.4
Smith, P.5
Muramatsu, M.6
-
60
-
-
77649222741
-
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
-
Nowak D., Ogawa S., Muschen M., Kato M., Kawamata N., Meixel A., et al. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 2010, 115:1049-1053.
-
(2010)
Blood
, vol.115
, pp. 1049-1053
-
-
Nowak, D.1
Ogawa, S.2
Muschen, M.3
Kato, M.4
Kawamata, N.5
Meixel, A.6
-
61
-
-
72849144434
-
Sequencing technologies [mdash] the next generation
-
Metzker M.L. Sequencing technologies [mdash] the next generation. Nat Rev Genet 2010, 11:31-46.
-
(2010)
Nat Rev Genet
, vol.11
, pp. 31-46
-
-
Metzker, M.L.1
-
62
-
-
0017653321
-
Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage
-
Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977, 63:125-130.
-
(1977)
Am J Med
, vol.63
, pp. 125-130
-
-
Fialkow, P.J.1
Jacobson, R.J.2
Papayannopoulou, T.3
-
63
-
-
13344262695
-
Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis
-
Sirard C., Lapidot T., Vormoor J., Cashman J., Doedens M., Murdoch B., et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 1996, 87:1539-1548.
-
(1996)
Blood
, vol.87
, pp. 1539-1548
-
-
Sirard, C.1
Lapidot, T.2
Vormoor, J.3
Cashman, J.4
Doedens, M.5
Murdoch, B.6
-
64
-
-
0033568250
-
Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
-
Holyoake T., Jiang X., Eaves C., Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064.
-
(1999)
Blood
, vol.94
, pp. 2056-2064
-
-
Holyoake, T.1
Jiang, X.2
Eaves, C.3
Eaves, A.4
-
65
-
-
0036090222
-
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
-
Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
-
(2002)
Blood
, vol.99
, pp. 319-325
-
-
Graham, S.M.1
Jorgensen, H.G.2
Allan, E.3
Pearson, C.4
Alcorn, M.J.5
Richmond, L.6
-
66
-
-
62649139996
-
Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation
-
Abrahamsson A.E., Geron I., Gotlib J., Dao K.-H.T., Barroga C.F., Newton I.G., et al. Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci 2009, 106:3925-3929.
-
(2009)
Proc Natl Acad Sci
, vol.106
, pp. 3925-3929
-
-
Abrahamsson, A.E.1
Geron, I.2
Gotlib, J.3
Dao, K.-H.T.4
Barroga, C.F.5
Newton, I.G.6
-
67
-
-
76249087423
-
TGF-[bgr]-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
-
Naka K., Hoshii T., Muraguchi T., Tadokoro Y., Ooshio T., Kondo Y., et al. TGF-[bgr]-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463:676-680.
-
(2010)
Nature
, vol.463
, pp. 676-680
-
-
Naka, K.1
Hoshii, T.2
Muraguchi, T.3
Tadokoro, Y.4
Ooshio, T.5
Kondo, Y.6
-
68
-
-
64749091867
-
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
-
Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
-
(2009)
Nature
, vol.458
, pp. 776-779
-
-
Zhao, C.1
Chen, A.2
Jamieson, C.H.3
Fereshteh, M.4
Abrahamsson, A.5
Blum, J.6
-
69
-
-
33749987744
-
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon
-
Breccia M., Diverio D., Pane F., Nanni M., Russo E., Biondo F., et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 2006, 30:1577-1579.
-
(2006)
Leuk Res
, vol.30
, pp. 1577-1579
-
-
Breccia, M.1
Diverio, D.2
Pane, F.3
Nanni, M.4
Russo, E.5
Biondo, F.6
-
70
-
-
33846023983
-
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
-
Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
-
(2007)
Blood
, vol.109
, pp. 58-60
-
-
Rousselot, P.1
Huguet, F.2
Rea, D.3
Legros, L.4
Cayuela, J.M.5
Maarek, O.6
-
72
-
-
42549142280
-
Getting to the stem of chronic myeloid leukaemia
-
Savona M., Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008, 8:341-350.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 341-350
-
-
Savona, M.1
Talpaz, M.2
-
73
-
-
61849163272
-
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
-
Quintas-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
-
(2009)
Blood
, vol.113
, pp. 1619-1630
-
-
Quintas-Cardama, A.1
Cortes, J.2
-
74
-
-
9144234689
-
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
-
Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004, 64:672-677.
-
(2004)
Cancer Res
, vol.64
, pp. 672-677
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
Lin, H.4
Arlinghaus, R.5
Aggarwal, B.B.6
-
75
-
-
67651174451
-
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
-
Grosso S., Puissant A., Dufies M., Colosetti P., Jacquel A., Lebrigand K., et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 2009, 8:1924-1933.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1924-1933
-
-
Grosso, S.1
Puissant, A.2
Dufies, M.3
Colosetti, P.4
Jacquel, A.5
Lebrigand, K.6
-
76
-
-
0037438640
-
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
-
Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
-
(2003)
Blood
, vol.101
, pp. 690-698
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
Gallick, G.4
Lin, H.5
Arlinghaus, R.6
-
77
-
-
0029683347
-
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells
-
Danhauser-Riedl S., Warmuth M., Druker B.J., Emmerich B., Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996, 56:3589-3596.
-
(1996)
Cancer Res
, vol.56
, pp. 3589-3596
-
-
Danhauser-Riedl, S.1
Warmuth, M.2
Druker, B.J.3
Emmerich, B.4
Hallek, M.5
-
78
-
-
0032969381
-
Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth
-
Roginskaya V., Zuo S., Caudell E., Nambudiri G., Kraker A.J., Corey S.J. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999, 13:855-861.
-
(1999)
Leukemia
, vol.13
, pp. 855-861
-
-
Roginskaya, V.1
Zuo, S.2
Caudell, E.3
Nambudiri, G.4
Kraker, A.J.5
Corey, S.J.6
-
79
-
-
2442465000
-
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
-
Hu Y., Liu Y., Pelletier S., Buchdunger E., Warmuth M., Fabbro D., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004, 36:453-461.
-
(2004)
Nat Genet
, vol.36
, pp. 453-461
-
-
Hu, Y.1
Liu, Y.2
Pelletier, S.3
Buchdunger, E.4
Warmuth, M.5
Fabbro, D.6
-
80
-
-
46849114097
-
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
-
Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008, 100:926-939.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 926-939
-
-
Wu, J.1
Meng, F.2
Kong, L.Y.3
Peng, Z.4
Ying, Y.5
Bornmann, W.G.6
-
82
-
-
33750303818
-
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
-
Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006, 12:5869-5878.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5869-5878
-
-
Fiskus, W.1
Pranpat, M.2
Balasis, M.3
Bali, P.4
Estrella, V.5
Kumaraswamy, S.6
-
83
-
-
0033214222
-
ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia
-
Asimakopoulos F.A., Shteper P.J., Krichevsky S., Fibach E., Polliack A., Rachmilewitz E., et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999, 94:2452-2460.
-
(1999)
Blood
, vol.94
, pp. 2452-2460
-
-
Asimakopoulos, F.A.1
Shteper, P.J.2
Krichevsky, S.3
Fibach, E.4
Polliack, A.5
Rachmilewitz, E.6
-
84
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
Cortes, J.4
Shah, S.5
Ayala, M.6
-
85
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.W.2
Issaragrisil, S.3
le Coutre, P.4
Etienne, G.5
Lobo, C.6
-
86
-
-
68949106066
-
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance
-
Zhang W.W., Cortes J.E., Yao H., Zhang L., Reddy N.G., Jabbour E., et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009, 27:3642-3649.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3642-3649
-
-
Zhang, W.W.1
Cortes, J.E.2
Yao, H.3
Zhang, L.4
Reddy, N.G.5
Jabbour, E.6
-
87
-
-
75649084233
-
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
-
McWeeney S.K., Pemberton L.C., Loriaux M.M., Vartanian K., Willis S.G., Yochum G., et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115:315-325.
-
(2010)
Blood
, vol.115
, pp. 315-325
-
-
McWeeney, S.K.1
Pemberton, L.C.2
Loriaux, M.M.3
Vartanian, K.4
Willis, S.G.5
Yochum, G.6
-
88
-
-
75749105885
-
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study
-
Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.W., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28:424-430.
-
(2010)
J Clin Oncol
, vol.28
, pp. 424-430
-
-
Cortes, J.E.1
Baccarani, M.2
Guilhot, F.3
Druker, B.J.4
Branford, S.5
Kim, D.W.6
-
89
-
-
66549108340
-
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
-
Baccarani M., Rosti G., Castagnetti F., Haznedaroglu I., Porkka K., Abruzzese E., et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
-
(2009)
Blood
, vol.113
, pp. 4497-4504
-
-
Baccarani, M.1
Rosti, G.2
Castagnetti, F.3
Haznedaroglu, I.4
Porkka, K.5
Abruzzese, E.6
-
90
-
-
73349122639
-
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
-
Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6041-6051
-
-
Baccarani, M.1
Cortes, J.2
Pane, F.3
Niederwieser, D.4
Saglio, G.5
Apperley, J.6
-
91
-
-
64049099666
-
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
-
Jabbour E., Kantarjian H.M., Jones D., Shan J., O'Brien S., Reddy N., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154-2160.
-
(2009)
Blood
, vol.113
, pp. 2154-2160
-
-
Jabbour, E.1
Kantarjian, H.M.2
Jones, D.3
Shan, J.4
O'Brien, S.5
Reddy, N.6
-
92
-
-
19944428353
-
Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
-
Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
-
(2004)
J Med Chem
, vol.47
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
Norris, D.4
Barrish, J.C.5
Behnia, K.6
-
93
-
-
37049014938
-
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
-
Rix U., Hantschel O., Durnberger G., Remsing Rix L.L., Planyavsky M., Fernbach N.V. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110:4055-4063.
-
(2007)
Blood
, vol.110
, pp. 4055-4063
-
-
Rix, U.1
Hantschel, O.2
Durnberger, G.3
Remsing Rix, L.L.4
Planyavsky, M.5
Fernbach, N.V.6
-
94
-
-
70149105272
-
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
-
Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
-
(2009)
Cancer
, vol.115
, pp. 4136-4147
-
-
Kantarjian, H.1
Pasquini, R.2
Levy, V.3
Jootar, S.4
Holowiecki, J.5
Hamerschlak, N.6
-
95
-
-
45149087139
-
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
-
Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22:1200-1206.
-
(2008)
Leukemia
, vol.22
, pp. 1200-1206
-
-
Hochhaus, A.1
Baccarani, M.2
Deininger, M.3
Apperley, J.F.4
Lipton, J.H.5
Goldberg, S.L.6
-
96
-
-
59549084574
-
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
-
Palandri F., Castagnetti F., Alimena G., Testoni N., Breccia M., Luatti S., et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009, 94:205-212.
-
(2009)
Haematologica
, vol.94
, pp. 205-212
-
-
Palandri, F.1
Castagnetti, F.2
Alimena, G.3
Testoni, N.4
Breccia, M.5
Luatti, S.6
-
97
-
-
0037093092
-
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
-
Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
-
(2002)
Blood
, vol.99
, pp. 3530-3539
-
-
Sawyers, C.L.1
Hochhaus, A.2
Feldman, E.3
Goldman, J.M.4
Miller, C.B.5
Ottmann, O.G.6
-
98
-
-
70249141675
-
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
-
Apperley J.F., Cortes J.E., Kim D.W., Roy L., Roboz G.J., Rosti G., et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009, 27:3472-3479.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3472-3479
-
-
Apperley, J.F.1
Cortes, J.E.2
Kim, D.W.3
Roy, L.4
Roboz, G.J.5
Rosti, G.6
-
99
-
-
67650607999
-
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
-
Kantarjian H., Cortes J., Kim D.W., Dorlhiac-Llacer P., Pasquini R., DiPersio J., et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009, 113:6322-6329.
-
(2009)
Blood
, vol.113
, pp. 6322-6329
-
-
Kantarjian, H.1
Cortes, J.2
Kim, D.W.3
Dorlhiac-Llacer, P.4
Pasquini, R.5
DiPersio, J.6
-
100
-
-
57849159300
-
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
-
Cortes J., Kim D.W., Raffoux E., Martinelli G., Ritchie E., Roy L., et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008, 22:2176-2183.
-
(2008)
Leukemia
, vol.22
, pp. 2176-2183
-
-
Cortes, J.1
Kim, D.W.2
Raffoux, E.3
Martinelli, G.4
Ritchie, E.5
Roy, L.6
-
101
-
-
72149119119
-
Current role of stem cell transplantation in chronic myeloid leukaemia
-
Gratwohl A., Heim D. Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:431-443.
-
(2009)
Best Pract Res Clin Haematol
, vol.22
, pp. 431-443
-
-
Gratwohl, A.1
Heim, D.2
-
102
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E., Manley P.W., Breitenstein W., Brüggen J., Cowan-Jacob S.W., Ray A., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
-
(2005)
Cancer Cell
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
Brüggen, J.4
Cowan-Jacob, S.W.5
Ray, A.6
-
103
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
-
(2006)
N Engl J Med
, vol.354
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
Bhalla, K.4
O'Brien, S.5
Wassmann, B.6
-
104
-
-
77955450607
-
Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or --intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study
-
Nicolini F.E., Kim D.-W., Ceglarek B., Turkina A., Alimena G., Al-Ali H.K., et al. Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or --intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. ASH Annual Meeting Abstracts 2009, 114:2201-
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Nicolini, F.E.1
Kim, D.-W.2
Ceglarek, B.3
Turkina, A.4
Alimena, G.5
Al-Ali, H.K.6
-
105
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
-
(2007)
Blood
, vol.110
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
Bhalla, K.4
Alimena, G.5
Palandri, F.6
-
106
-
-
79551516839
-
Response and outcomes to nilotinib at 24months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations
-
Radich J.P., Martinelli G., Hochhaus A., Gottardi E., Soverini S., Branford S., et al. Response and outcomes to nilotinib at 24months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations. ASH Annual Meeting Abstracts 2009, 114:1130-
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Radich, J.P.1
Martinelli, G.2
Hochhaus, A.3
Gottardi, E.4
Soverini, S.5
Branford, S.6
-
107
-
-
77954659561
-
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
-
Giles F.J., Abruzzese E., Rosti G., Kim D.W., Bhatia R., Bosly A., et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2010, 24:1299-1301.
-
(2010)
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK
, vol.24
, pp. 1299-1301
-
-
Giles, F.J.1
Abruzzese, E.2
Rosti, G.3
Kim, D.W.4
Bhatia, R.5
Bosly, A.6
-
108
-
-
65649098667
-
Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 Study
-
le Coutre P.D., Giles F., Hochhaus A., Apperley J.F., Ossenkoppele G., Haque A., et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 Study. ASH Annual Meeting Abstracts 2008, 112:3229-
-
(2008)
ASH Annual Meeting Abstracts
, vol.112
-
-
le Coutre, P.D.1
Giles, F.2
Hochhaus, A.3
Apperley, J.F.4
Ossenkoppele, G.5
Haque, A.6
-
110
-
-
70349245253
-
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
-
Jabbour E., Jones D., Kantarjian H.M., O'Brien S., Tam C., Koller C., et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009, 114:2037-2043.
-
(2009)
Blood
, vol.114
, pp. 2037-2043
-
-
Jabbour, E.1
Jones, D.2
Kantarjian, H.M.3
O'Brien, S.4
Tam, C.5
Koller, C.6
-
111
-
-
70249105789
-
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
-
Hughes T., Saglio G., Branford S., Soverini S., Kim D.W., Muller M.C., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009, 27:4204-4210.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4204-4210
-
-
Hughes, T.1
Saglio, G.2
Branford, S.3
Soverini, S.4
Kim, D.W.5
Muller, M.C.6
-
112
-
-
47249123747
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
-
Jabbour E., Kantarjian H., Jones D., Breeden M., Garcia-Manero G., O'Brien S., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008, 112:53-55.
-
(2008)
Blood
, vol.112
, pp. 53-55
-
-
Jabbour, E.1
Kantarjian, H.2
Jones, D.3
Breeden, M.4
Garcia-Manero, G.5
O'Brien, S.6
-
113
-
-
0035829463
-
Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity
-
Boschelli D.H., Ye F., Wang Y.D., Dutia M., Johnson S.L., Wu B., et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001, 44:3965-3977.
-
(2001)
J Med Chem
, vol.44
, pp. 3965-3977
-
-
Boschelli, D.H.1
Ye, F.2
Wang, Y.D.3
Dutia, M.4
Johnson, S.L.5
Wu, B.6
-
114
-
-
0037439689
-
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice
-
Golas J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63:375-381.
-
(2003)
Cancer Res
, vol.63
, pp. 375-381
-
-
Golas, J.M.1
Arndt, K.2
Etienne, C.3
Lucas, J.4
Nardin, D.5
Gibbons, J.6
-
117
-
-
31344435118
-
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
-
Asaki T., Sugiyama Y., Hamamoto T., Higashioka M., Umehara M., Naito H., et al. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 2006, 16:1421-1425.
-
(2006)
Bioorg Med Chem Lett
, vol.16
, pp. 1421-1425
-
-
Asaki, T.1
Sugiyama, Y.2
Hamamoto, T.3
Higashioka, M.4
Umehara, M.5
Naito, H.6
-
118
-
-
28444479480
-
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
-
Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948-3954.
-
(2005)
Blood
, vol.106
, pp. 3948-3954
-
-
Kimura, S.1
Naito, H.2
Segawa, H.3
Kuroda, J.4
Yuasa, T.5
Sato, K.6
-
119
-
-
77952840150
-
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance
-
Kantarjian H., Coutre Pl, Cortes J., Pinilla-Ibarz J., Nagler A., Hochhaus A., et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010, 116:2665-2672.
-
(2010)
Cancer
, vol.116
, pp. 2665-2672
-
-
Kantarjian, H.1
Coutre, P.2
Cortes, J.3
Pinilla-Ibarz, J.4
Nagler, A.5
Hochhaus, A.6
-
120
-
-
4644368478
-
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
-
O'Hare T., Pollock R., Stoffregen E.P., Keats J.A., Abdullah O.M., Moseson E.M., et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004, 104:2532-2539.
-
(2004)
Blood
, vol.104
, pp. 2532-2539
-
-
O'Hare, T.1
Pollock, R.2
Stoffregen, E.P.3
Keats, J.A.4
Abdullah, O.M.5
Moseson, E.M.6
-
121
-
-
70350507997
-
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
-
O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
-
(2009)
Cancer Cell
, vol.16
, pp. 401-412
-
-
O'Hare, T.1
Shakespeare, W.C.2
Zhu, X.3
Eide, C.A.4
Rivera, V.M.5
Wang, F.6
-
122
-
-
77949674913
-
A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations
-
Cortes J., Talpaz M., Deininger M., Shah N., Flinn I.W., Mauro M.J., et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. ASH Annual Meeting Abstracts 2009, 114:643-
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Cortes, J.1
Talpaz, M.2
Deininger, M.3
Shah, N.4
Flinn, I.W.5
Mauro, M.J.6
-
123
-
-
77950949478
-
Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
-
Moore A.S., Blagg J., Linardopoulos S., Pearson A.D. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010, 24:671-678.
-
(2010)
Leukemia
, vol.24
, pp. 671-678
-
-
Moore, A.S.1
Blagg, J.2
Linardopoulos, S.3
Pearson, A.D.4
-
124
-
-
77950919574
-
Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia
-
Cortes-Franco J., Dombret H., Schafhausen P., Brummendorf T.H., Boissel N., Latini F., et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. ASH Annual Meeting Abstracts 2009, 114:864-
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Cortes-Franco, J.1
Dombret, H.2
Schafhausen, P.3
Brummendorf, T.H.4
Boissel, N.5
Latini, F.6
-
125
-
-
60549088370
-
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity†
-
Howard S., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Curry J., et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity†. J Med Chem 2008, 52:379-388.
-
(2008)
J Med Chem
, vol.52
, pp. 379-388
-
-
Howard, S.1
Berdini, V.2
Boulstridge, J.A.3
Carr, M.G.4
Cross, D.M.5
Curry, J.6
-
126
-
-
77957201111
-
Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells
-
[blood-2009-03-211466]
-
Tanaka R., Squires M.S., Kimura S., Yokota A., Nagao R., Yamauchi T., et al. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood 2010, [blood-2009-03-211466].
-
(2010)
Blood
-
-
Tanaka, R.1
Squires, M.S.2
Kimura, S.3
Yokota, A.4
Nagao, R.5
Yamauchi, T.6
-
127
-
-
64349094896
-
A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies
-
Ravandi F., Foran J., Verstovsek S., Cortes J., Wierda W., Boone P., et al. A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. ASH Annual Meeting Abstracts 2007, 110:904-
-
(2007)
ASH Annual Meeting Abstracts
, vol.110
-
-
Ravandi, F.1
Foran, J.2
Verstovsek, S.3
Cortes, J.4
Wierda, W.5
Boone, P.6
-
128
-
-
72249090201
-
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009
-
Quintás-Cardama A., Kantarjian H., Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009, 115:5382-5393.
-
(2009)
Cancer
, vol.115
, pp. 5382-5393
-
-
Quintás-Cardama, A.1
Kantarjian, H.2
Cortes, J.3
-
129
-
-
77957089790
-
Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study
-
Cortes-Franco J., Raghunadharao D., Parikh P., Wetzler M., Lipton J.H., Jones D., et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study. ASH Annual Meeting Abstracts 2009, 114:861-
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Cortes-Franco, J.1
Raghunadharao, D.2
Parikh, P.3
Wetzler, M.4
Lipton, J.H.5
Jones, D.6
-
130
-
-
77950394312
-
Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2/3 study
-
Cortes-Franco J., Khoury H.J., Nicolini F.E., Corm S., Lipton J.H., Jones D., et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2/3 study. ASH Annual Meeting Abstracts 2009, 114:644-
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
-
-
Cortes-Franco, J.1
Khoury, H.J.2
Nicolini, F.E.3
Corm, S.4
Lipton, J.H.5
Jones, D.6
-
131
-
-
43749121647
-
DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model
-
Van Etten R.A., Chan W.W., Zaleskas V.M., Evangelista P., Lazarides K., Peng C., et al. DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. ASH Annual Meeting Abstracts 2007, 110:463-
-
(2007)
ASH Annual Meeting Abstracts
, vol.110
-
-
Van Etten, R.A.1
Chan, W.W.2
Zaleskas, V.M.3
Evangelista, P.4
Lazarides, K.5
Peng, C.6
-
132
-
-
68949087742
-
Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I
-
Van Etten R.A., Chan W.W., Zaleskas V.M., Walz C., Evangelista P., Lazarides K., et al. Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I. ASH Annual Meeting Abstracts 2008, 112:576-
-
(2008)
ASH Annual Meeting Abstracts
, vol.112
-
-
Van Etten, R.A.1
Chan, W.W.2
Zaleskas, V.M.3
Walz, C.4
Evangelista, P.5
Lazarides, K.6
-
133
-
-
0028813711
-
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
-
Kantarjian H.M., Smith T.L., O'Brien S., Beran M., Pierce S., Talpaz M., et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995, 122:254-261.
-
(1995)
Ann Intern Med
, vol.122
, pp. 254-261
-
-
Kantarjian, H.M.1
Smith, T.L.2
O'Brien, S.3
Beran, M.4
Pierce, S.5
Talpaz, M.6
-
134
-
-
77956035133
-
The response to imatinib and interferon-{alpha} is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
-
Palandri F., Castagnetti F., Iacobucci I., Martinelli G., Amabile M., Gugliotta G., et al. The response to imatinib and interferon-{alpha} is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 2010, 95:1415-1419.
-
(2010)
Haematologica
, vol.95
, pp. 1415-1419
-
-
Palandri, F.1
Castagnetti, F.2
Iacobucci, I.3
Martinelli, G.4
Amabile, M.5
Gugliotta, G.6
-
135
-
-
77950496740
-
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia
-
Burchert A., Muller M.C., Kostrewa P., Erben P., Bostel T., Liebler S., et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010, 28:1429-1435.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1429-1435
-
-
Burchert, A.1
Muller, M.C.2
Kostrewa, P.3
Erben, P.4
Bostel, T.5
Liebler, S.6
-
136
-
-
71849109054
-
Response definitions and European Leukemianet Management recommendations
-
Baccarani M., Castagnetti F., Gugliotta G., Palandri F., Soverini S. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol 2009, 22:331-341.
-
(2009)
Best Pract Res Clin Haematol
, vol.22
, pp. 331-341
-
-
Baccarani, M.1
Castagnetti, F.2
Gugliotta, G.3
Palandri, F.4
Soverini, S.5
-
137
-
-
41349083969
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
-
le Coutre P., Ottmann O.G., Giles F., Kim D.W., Cortes J., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111:1834-1839.
-
(2008)
Blood
, vol.111
, pp. 1834-1839
-
-
le Coutre, P.1
Ottmann, O.G.2
Giles, F.3
Kim, D.W.4
Cortes, J.5
Gattermann, N.6
-
139
-
-
67349137674
-
A phase I dose escalation study of kw-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML
-
Cortes J., Roboz G.J., Kantarjian H.M., Feldman E.J., Karp J.E., Pratz K.W., et al. A phase I dose escalation study of kw-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML. ASH Annual Meeting Abstracts 2008, 112:2967-
-
(2008)
ASH Annual Meeting Abstracts
, vol.112
-
-
Cortes, J.1
Roboz, G.J.2
Kantarjian, H.M.3
Feldman, E.J.4
Karp, J.E.5
Pratz, K.W.6
-
140
-
-
33846240316
-
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
-
Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
-
(2007)
Blood
, vol.109
, pp. 500-502
-
-
Giles, F.J.1
Cortes, J.2
Jones, D.3
Bergstrom, D.4
Kantarjian, H.5
Freedman, S.J.6
|